公开(公告)号：US20110059087A1

公开(公告)日：2011-03-10

申请号：US12870199

申请日：2010-08-27

Applicant: Katherine E. Lewis ,  Scott R. Presnell ,  James W. West ,  Robert Mabry ,  Brent Meengs ,  Steven D. Levin

Inventor： Katherine E. Lewis ,  Scott R. Presnell ,  James W. West ,  Robert Mabry ,  Brent Meengs ,  Steven D. Levin

IPC: A61K39/395 ,  C07K16/24 ,  C12N5/0783 ,  A61P25/28 ,  A61P1/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract translation: 本发明涉及通过其p19亚基或IL-17和IL-23（通过p19）阻断，抑制，降低，拮抗或中和IL-17，IL-23的活性。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。

公开(公告)号：US20100113748A1

公开(公告)日：2010-05-06

申请号：US12580112

申请日：2009-10-15

Applicant: Rolf E. Kuestner ,  Zeren Gao ,  Steven D. Levin ,  Mark W. Rixon

Inventor： Rolf E. Kuestner ,  Zeren Gao ,  Steven D. Levin ,  Mark W. Rixon

IPC: C07K16/00 ,  C07K14/00

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K2121/00 ,  C07K14/715 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括使用可溶性IL-17RC受体IL-17RCx4来治疗炎症的方法。

公开(公告)号：US20110177083A1

公开(公告)日：2011-07-21

申请号：US13015304

申请日：2011-01-27

Applicant: Scott R. Presnell ,  Steven K. Burkhead ,  Steven D. Levin ,  Rolf E. Kuestner ,  Zeren Gao ,  Stephen R. Jaspers ,  Janine Bilsborough

Inventor： Scott R. Presnell ,  Steven K. Burkhead ,  Steven D. Levin ,  Rolf E. Kuestner ,  Zeren Gao ,  Stephen R. Jaspers ,  Janine Bilsborough

IPC: A61K39/395 ,  A61K38/17 ,  A61P25/28

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。

公开(公告)号：US20110159589A1

公开(公告)日：2011-06-30

申请号：US13032501

申请日：2011-02-22

Applicant: Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  George Robert Mabry, III ,  Stephen R. Jaspers ,  Monica J. Huber

Inventor： Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  George Robert Mabry, III ,  Stephen R. Jaspers ,  Monica J. Huber

IPC: C12N5/02

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S530/809

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。

公开(公告)号：US07910703B2

公开(公告)日：2011-03-22

申请号：US12111117

申请日：2008-04-28

Applicant: Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  George Robert Mabry, III ,  Stephen R. Jaspers ,  Monica J. Huber

Inventor： Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  George Robert Mabry, III ,  Stephen R. Jaspers ,  Monica J. Huber

IPC: C12P21/08

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S530/809

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。

公开(公告)号：US07842665B2

公开(公告)日：2010-11-30

申请号：US12370309

申请日：2009-02-12

Applicant: Steven D. Levin ,  Mark W. Rixon ,  Zeren Gao

Inventor： Steven D. Levin ,  Mark W. Rixon ,  Zeren Gao

IPC: A61K38/00

CPC classification number: C07K14/54 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12P21/02 ,  Y02A50/401

Abstract: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.

Abstract translation: 本发明涉及IL-17A和IL-17F的拮抗剂。 本发明的拮抗剂基于单独的IL-17RC或IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）两者。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RA是IL-17A的受体，IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括可溶性IL-17A和IL-17F拮抗剂，以及使用它们的方法。

公开(公告)号：US20090156495A1

公开(公告)日：2009-06-18

申请号：US12270775

申请日：2008-11-13

Applicant: Zeren Gao ,  Steven D. Levin ,  Janine Bilsborough ,  James W. West ,  Cameron S. Brandt ,  Frederick J. Ramsdell ,  Edward D. Howard ,  Eric M. Chadwick

Inventor： Zeren Gao ,  Steven D. Levin ,  Janine Bilsborough ,  James W. West ,  Cameron S. Brandt ,  Frederick J. Ramsdell ,  Edward D. Howard ,  Eric M. Chadwick

IPC: A61K38/17 ,  C07K14/47 ,  C07K19/00

CPC classification number: C07K16/2827 ,  A61K38/00 ,  A61K2039/507 ,  C07K14/47 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12Q1/66 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/70532

Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Abstract translation: 本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子，并在T细胞上表达。 本发明还提供了zB7R1与CD155结合的能力的发现。 还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。

公开(公告)号：US20090155271A1

公开(公告)日：2009-06-18

申请号：US12370309

申请日：2009-02-12

Applicant: STEVEN D. LEVIN ,  MARK W. RIXON ,  ZEREN GAO

Inventor： STEVEN D. LEVIN ,  MARK W. RIXON ,  ZEREN GAO

IPC: A61K39/395 ,  C07K14/00 ,  C07K16/18 ,  C12N15/11 ,  C12N15/00 ,  C12N5/06 ,  C12P21/02 ,  A61K38/16

CPC classification number: C07K14/54 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12P21/02 ,  Y02A50/401

Abstract: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.

Abstract translation: 本发明涉及IL-17A和IL-17F的拮抗剂。 本发明的拮抗剂单独使用IL-17RC或IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RA是IL-17A的受体，IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括可溶性IL-17A和IL-17F拮抗剂，以及使用它们的方法。

公开(公告)号：US20080299129A1

公开(公告)日：2008-12-04

申请号：US12111117

申请日：2008-04-28

Applicant: Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  George Robert Mabry, III ,  Stephen R. Jaspers ,  Monica J. Huber

Inventor： Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  George Robert Mabry, III ,  Stephen R. Jaspers ,  Monica J. Huber

IPC: A61K39/395 ,  C07K16/24 ,  A61P19/02 ,  A61P3/10 ,  A61P9/10 ,  A61P11/06 ,  A61P17/06 ,  A61P1/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S530/809

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。

公开(公告)号：US08496936B2

公开(公告)日：2013-07-30

申请号：US13534019

申请日：2012-06-27

Applicant: Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  Robert Mabry ,  Stephen R. Jaspers ,  Monica J. Huber

Inventor： Katherine E. Lewis ,  Scott R. Presnell ,  Steven D. Levin ,  Robert Mabry ,  Stephen R. Jaspers ,  Monica J. Huber

IPC: A61K39/00 ,  A61K39/395

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S530/809

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.